Pancreatic Cancer Research

ResearcherChinese PLA General HospitalActive in the last 2 years

Zhiming Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2844-3503; OpenAlex author ID A5102791385. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2014: 3 papers · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 17

  1. Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter propensit… Co-author DOI 10.1016/j.hbpd.2026.06.001↗
  2. New-onset diabetes worsens prognosis of patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter study. Co-author DOI 10.1016/j.hbpd.2025.04.008↗
  3. Recognizing significance of propensity score matching and clinical practice in evaluating oncological survivals of pancreatic cancer. Co-author DOI 10.21037/hbsn-24-615↗
  4. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center. Co-author DOI 10.1016/j.hbpd.2022.09.006↗
  5. Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hbpd.2022.09.009↗
  6. Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study. Co-author DOI 10.1097/js9.0000000000000296↗
  7. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02321-7↗
  8. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduod… Co-author DOI 10.1016/j.ijsu.2022.106891↗
  9. Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.16573↗
  10. Methylation patterns partition pancreatic cancer into distinct prognostic subtypes. Co-author DOI 10.2217/fon-2020-0804↗
  11. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. First author DOI 10.12998/wjcc.v8.i13.2778↗
  12. A novel epigenetic signature for predicting the prognosis of pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-27415/v1↗
  13. Clinical Significance of Preoperative CD8+ Central Memory T Cells for Operable Pancreatic Adenocarcinoma. Co-author DOI 10.1159/000440681↗
  14. [Preoperative neutrophil-lymphocyte ratio as an independent prognostic predictor for pancreatic cancer]. Co-author PMID 26710955↗
  15. Plasma ferritin levels, HFE polymorphisms, and risk of pancreatic cancer among Chinese Han population. Co-author DOI 10.1007/s13277-014-1978-x↗
  16. Influence of the c.1517G>C genetic variant in the XRCC1 gene on pancreatic cancer susceptibility in a Chinese population. Co-author DOI 10.4238/2014.june.16.5↗
  17. Association of c.461G>A genetic variant of OGG1 gene with pancreatic cancer susceptibility in Chinese. Co-author DOI 10.4238/2014.september.5.10↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rong Liu · 16 shared papers, 2014–2026 · strength 2.49
  2. Xiuping Zhang · 7 shared papers, 2022–2026 · strength 1.36
  3. Minggen Hu · 6 shared papers, 2015–2023 · strength 0.86
  4. Qu Liu · 4 shared papers, 2021–2023 · strength 0.66
  5. Shuai Xu · 3 shared papers, 2022–2025 · strength 0.56
  6. Shuai Xu · 3 shared papers, 2022–2023 · strength 0.55
  7. Wenbo Zou · 2 shared papers, 2023–2025 · strength 0.52
  8. Peizi Liu · 2 shared papers, 2025–2026 · strength 0.48
  9. Wan Yee Lau · 3 shared papers, 2021–2023 · strength 0.46
  10. Tan X · 2 shared papers, 2020–2021 · strength 0.33
  11. Ye Xu · 1 shared paper, 2025 · strength 0.33
  12. Nan Jiang · 2 shared papers, 2020–2022 · strength 0.25
  13. Kai Liu · 1 shared paper, 2026 · strength 0.25
  14. Xiaodong Tan · 1 shared paper, 2025 · strength 0.23
  15. Dabin Xu · 1 shared paper, 2021 · strength 0.17
  16. Chenggang Li · 2 shared papers, 2014–2020 · strength 0.16
  17. Guanghai Dai · 1 shared paper, 2022 · strength 0.15
  18. Xiu‐Ping Zhang · 1 shared paper, 2021 · strength 0.13
  19. Yuzhen Gao · 1 shared paper, 2021 · strength 0.13
  20. Yongjie Wu · 2 shared papers, 2015 · strength 0.12
  21. Zhuzeng Yin · 1 shared paper, 2020 · strength 0.11
  22. Hailiang Liu · 1 shared paper, 2015 · strength 0.06
  23. Ruihua Liu · 1 shared paper, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.